Inspections, Compliance, Enforcement, and Criminal Investigations
Rebuilder Medical, Inc. - Close Out 4/10/11
Department of Health and Human Services
|Public Health Service|
Food and Drug Administration
Baltimore District Office
August 10, 2011
RETURN RECEIPT REQUESTED
Dr. David B. Phillips, CEO
ReBuilder Medical, Inc.
636 Treeline Drive
Charles Town, WV 25414
Dear Dr. Phillips:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter 167912 dated March 8, 2011. Based on our evaluation, it appears that you have adequately addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.